MET and neoplasm: While MET-CAR.CD28ζ is preferred for future development, the architecture of the CAR construct as well as strategies to compensate for tumor microenvironment-mediated CAR-T cell exhaustion are necessary to enhance MET-CAR-T cell therapeutic efficacy.